Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Tesamorelin Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Theratechnologies Receives March 2025 PDUFA Date
    Theratechnologies Receives March 2025 PDUFA Date

    10 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/10/2994926/0/en/Theratechnologies-Receives-March-2025-PDUFA-Goal-Date-for-Updated-Tesamorelin-F8-Formulation-sBLA.html

    GLOBENEWSWIRE
    10 Dec 2024
    Share Share
    Theratechnologies Submit Updated Tesamorelin F8 sBLA for FDA Review
    Theratechnologies Submit Updated Tesamorelin F8 sBLA for FDA Review

    26 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/26/2987389/0/en/Theratechnologies-Submits-Updated-Tesamorelin-F8-Formulation-sBLA-for-FDA-Review.html

    GLOBENEWSWIRE
    26 Nov 2024
    Share Share
    Theratechnologies Warns Of Egrifta Supply Disruption After Plant Shutdown
    Theratechnologies Warns Of Egrifta Supply Disruption After Plant Shutdown

    18 Sep 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/theratechnologies-warns-hiv-med-disruption-after-third-party-plant-shutdown

    FIERCE PHARMA
    18 Sep 2024
    Share Share
    Theratechnologies Announces Risk of EGRIFTA SV® Supply Disruption
    Theratechnologies Announces Risk of EGRIFTA SV® Supply Disruption

    17 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/17/2947862/0/en/Theratechnologies-Announces-a-Risk-of-a-Temporary-Supply-Disruption-for-EGRIFTA-SV-in-Early-2025.html

    GLOBENEWSWIRE
    17 Sep 2024
    Share Share
    FDA declines to approve new form of HIV-associated lipodystrophy drug
    FDA declines to approve new form of HIV-associated lipodystrophy drug

    25 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/01/24/2815109/0/en/Theratechnologies-Receives-Complete-Response-Letter-CRL-from-the-FDA-for-the-F8-Formulation-of-Tesamorelin-sBLA.html

    GLOBENEWSWIRE
    25 Jan 2024
    Share Share
    Theratechnologies Receives Update from FDA on Tesamorelin F8 sBLA
    Theratechnologies Receives Update from FDA on Tesamorelin F8 sBLA

    23 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/23/2813983/0/en/Theratechnologies-Receives-Update-from-FDA-on-Tesamorelin-F8-Supplemental-Biologic-License-Application.html

    GLOBENEWSWIRE
    23 Jan 2024
    Share Share